Aspire Biopharma Holdings Inc (ASBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,857 | 1,004 | 1,948 | 206 | 1,347 |
| Inventories | 370 | 253 | 35 | N/A | N/A |
| TOTAL | $7,117 | $1,312 | $2,403 | $989 | $1,966 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $7,117 | $1,312 | $2,403 | $989 | $1,966 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 2,791 | 6,240 | 5,643 | 5,054 |
| Accounts payable and accrued liabilities | 1,653 | 2,377 | 1,415 | 2,084 | 1,786 |
| Accrued Expenses | N/A | N/A | 267 | N/A | 319 |
| Other current liabilities | N/A | 41 | 3,554 | N/A | N/A |
| TOTAL | $3,152 | $7,593 | $13,861 | $10,557 | $9,869 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 96 | 96 | 10 | 49 | 49 |
| TOTAL | $96 | $96 | $10 | $49 | $49 |
| Total Liabilities | $3,249 | $7,689 | $13,870 | $10,606 | $9,918 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,295 | 167 | 89 | 41 | 41 |
| Common Shares | 0 | 0 | 5 | 5 | 5 |
| Retained earnings | -30,481 | -27,258 | -22,550 | -20,700 | -18,719 |
| TOTAL | $3,869 | $-6,376 | $-11,467 | $-9,617 | $-7,953 |
| Total Liabilities And Equity | $7,117 | $1,312 | $2,403 | $989 | $1,966 |